生物利用度
体内
乙型肝炎表面抗原
肝细胞
HBeAg
脂质体
乙型肝炎病毒
体外
药理学
化学
黄芩苷
药代动力学
分子生物学
生物
病毒
病毒学
生物化学
高效液相色谱法
生物技术
色谱法
作者
Weiming Xu,Yijun Niu,Xin Ai,Chengjie Xia,Ping Geng,Haiyan Zhu,Wei Zhou,Hai Huang,Xunlong Shi
出处
期刊:Biomedicines
[MDPI AG]
日期:2022-04-14
卷期号:10 (4): 900-900
被引量:11
标识
DOI:10.3390/biomedicines10040900
摘要
The anti-hepatitis B virus (HBV) efficacy of baicalin (BA) is mediated by HBV-related hepatocyte nuclear factors (HNFs). However, this efficacy is severely limited by the low bioavailability of BA. Therefore, a novel liver-targeted BA liposome was constructed to promote the bioavailability and antiviral ability of BA. The results showed that apolipoprotein A1 (ApoA1)-modified liposomes (BAA1) significantly enhanced BA's cellular uptake and specific distribution in the liver. Furthermore, the substantial inhibitory effects of BAA1 on HBsAg, HBeAg, HBV RNA, and HBV DNA were assessed in HB-infected cells and mice. Western blotting, co-immunoprecipitation, and transcriptomics analysis further revealed that the enhanced anti-HBV efficacy of BAA1 was attributed to the interaction between hepatocyte nuclear factors (HNFs) and estrogen receptors (ERs). Based on the findings, we propose that the ApoA1-modified liposomes aid BA in inhibiting HBV transcription and replication by augmenting its bioavailability and the HNFs-ERs axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI